Hostname: page-component-5c6d5d7d68-xq9c7 Total loading time: 0 Render date: 2024-08-16T19:49:38.120Z Has data issue: false hasContentIssue false
  • English
  • Français

Biochemical Aspects of the Pharmacology of Moclobemide

The Implications of Animal Studies

Published online by Cambridge University Press:  06 August 2018

B.A. Callingham
B.A. Callingham*
Affiliation:
Department of Pharmacology, University of Cambridge, UK
Get access Rights & Permissions [Opens in a new window]

Abstract

Administration of moclobemide – a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A) – to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally. The ability of moclobemide to potentiate the pharmacological actions of amine substrates for MAO-A in in vitro preparations is very weak, unless the drug is ‘activated’ by prior incubation with the tissues. However, animal experiments, both in vitro and in vivo, can give realistic indications not only of the mode of action of inhibitors of MAO and any toxicity, but also, in the case of MAO inhibitors, of the chance of potentially life-threatening hypertensive crises following inadvertent ingestion of amine-containing food or medicaments. Animal tests may also reveal any influence MAOIs have on amines released from non-neuronal stores.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 53 - 60
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ask, A.L., Hellstrom, W., Norrman, S., et al (1982) Selective inhibition of the A form of monoamine oxidase by 4-dimethylamino-alpha-methylphenylalkylamine derivatives in the rat. Neuropharmacology, 21, 299–308.Google Scholar
Ask, A.L., Fagervall, I. & Ross, S.B. (1984) Amiflamine [FLA 336 (+)], a reversible inhibitor selective for serotoninergic neurones. In Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors (eds Tipton, K.F., Strolin Benedetti, M. & Dostert, P.). London: Academic Press.Google Scholar
Bieck, P., Antonin, K.H. & Jedrychowski, M. (1983) Monoamine oxidase inhibition in healthy volunteers by CGP 11305 A, a new specific inhibitor of MAO-A. Modern Problems in Pharmacopsychiatry, 19, 352–358.Google Scholar
Bieck, P., Antonin, K.H., Cremer, G., et al (1984) Tyramine pressor effects of CGP 11305 A in comparison to tranylcypromine after prolonged treatment of human volunteers. In Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors (eds Tipton, K.F., Strolin Benedetti, M. & Dostert, P.). London: Academic Press.Google Scholar
Blackwell, B. (1963) Hypertensive crises due to monoamine oxidase inhibitors. Lancet, ii, 849–851.Google Scholar
Blackwell, B. & Marley, E. (1966) Interactions with cheese and its constituents with monoamine oxidase inhibitors. British Journal of Pharmacology and Chemotherapy, 26, 120–141.Google Scholar
Blackwell, B., Marley, E., Price, J., et al (1967) Interactions of cheese and of its constituents with monoamine oxidase inhibitors. British Journal of Psychiatry, 113, 349–365.CrossRefGoogle Scholar
Burkard, W.P., Bonetti, E.P., Da Prada, M., et al. (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248, 391–399.Google Scholar
Burton, C.J., Callingham, B.A. & Morton, A.J. (1984) Some actions of moclobemide (Ro 11–1163) on MAO and on responses of the rat anococcygeus muscle to sympathomimetic amines. Journal of Pharmacy and Pharmacology, 36, 53W.Google Scholar
Callingham, B.A. (1986) Some aspects of monoamine oxidase pharmacology. Cell Biochemistry and Function, 4, 99–108.Google Scholar
Callingham, B.A. & Laverty, R. (1973) Studies on the nature of the increased monoamine oxidase activity in the rat heart after adrenalectomy. Journal of Pharmacy and Pharmacology, 25, 940–947.Google Scholar
Callingham, B.A. & McCarry, W.J. (1984) Pharmacological effects of MAO inhibitors on the anococcygeus muscle and perfused mesenteric arteries of the rat. In Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors (eds Tipton, K.F., Strolin Benedetti, M. & Dostert, P.). London: Academic Press.Google Scholar
Callingham, B.A. & Ovens, R.S. (1988) Some in vitro effects of moclobemide and other MAO inhibitors on responses to sympathomimetic amines. Journal of Neural Transmission 26 (Suppl.), 17–29.Google Scholar
Callingham, B.A., Mazel, P. & Porter, J.C. (1985) Some properties of amine oxidase activities in the rat intestine. British Journal of Pharmacology, 86, 553P.Google Scholar
Crane, G.E. (1957) Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatric Research Reports, 8, 142–152.Google Scholar
Da Prada, M., Keller, H.H., Kettler, R., et al (1982) Ro 11–1163, a specific and short-acting MAO inhibitor with antidepressant properties. In Monoamine Oxidase, Basic and Clinical Frontiers (eds Kamijo, K., Usdin, E. & Nagatsu, T.). Amsterdam: Excerpta Medica.Google Scholar
Da Prada, M., Kettler, R., Keller, H.H. et al (1983) Neurochemical effects in vitro and in vivo of the antidepressant Ro 11–1163, a specific and short-acting MAO-A inhibitor. Modern Problems in Pharmacopsychiatry, 19, 231–245.Google Scholar
Da Prada, M., Kettler, R., Burkhard, W.P., et al (1984) Moclobemide, an antidepressant with short-acting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors (eds Tipton, K.K., Strolin Benedetti, M. & Dostert, P.). London: Academic Press.Google Scholar
Da Prada, M., Kettler, R., Keller, H.H., et al (1986) Ro 16–6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. In Advances in Neurology Vol. 45 (eds Yahr, M.D. & Bergmann, K.J.). New York: Raven Press.Google Scholar
Da Prada, M., Kettler, R., Cesura, A.M., et al (1988a) Reversible enzyme-activated monoamine oxidase inhibitors: new advances. Pharmacological Research Communications, 20 (Suppl. IV), 21–33.Google Scholar
Da Prada, M., Kettler, R., Zurcher, G., Wüthrich, I., et al (1988b) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. Journal of Neural Transmission, 26 (Suppl.), 31–56.Google Scholar
Da Prada, M., Kettler, R., Cesura, A.M., et al (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248, 400–414.Google ScholarPubMed
Della Corte, L. & Callingham, B.A. (1977) The influence of age and adrenalectomy on rat heart monoamine oxidase. Biochemical Pharmacology, 26, 407–415.Google Scholar
Della Corte, L. & Tipton, K.F. (1980) The turnover of the A- and B-forms of monoamine oxidase in rat liver. Biochemical Pharmacology, 29, 811–815.Google Scholar
Finberg, J.P.M., Tenne, M. & Youdim, M.B.H. (1981) Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase. British Journal of Pharmacology, 73, 65–74.Google Scholar
Finberg, J.P.M., Tenne, M. & Youdim, M.B.H. (1982) Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. British Journal of Pharmacology, 77, 13–21.Google Scholar
Finberg, J.P.M. & Youdim, M.B.H. (1988) Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. Journal of Neural Transmission, 26 (Suppl.), 11–16.Google Scholar
Fowler, C.J. & Strolin Benedetti, M. (1983) Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. Journal of Neurochemistry, 40, 510–513.CrossRefGoogle ScholarPubMed
Fowler, C.J., Callingham, B.A., Mantle, T.J., et al (1978) Monoamine oxidase A and B: a useful concept? Biochemical Pharmacology, 27, 97–101.Google Scholar
Gillespie, J.S. (1972) The rat anococcygeus muscle and its response to nerve stimulation and to some drugs. British Journal of Pharmacology, 45, 404–416.Google Scholar
Gillespie, J.S. (1979) The physiology and pharmacology of the anococcygeus muscle. Trends in Pharmacological Sciences, 1, 453–457.Google Scholar
Hasan, F., McCrodden, J.M., Kennedy, N.P., et al (1988) The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. Journal of Neural Transmission, 26 (Suppl.), 1–9.Google ScholarPubMed
Jarrott, B. & Iversen, L.L. (1971) Noradrenaline metabolizing in normal and sympathetically denervated vas deferens. Journal of Neurochemistry, 18, 1–6.Google Scholar
Keller, H.H., Kettler, R., Keller, G., et al (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16–6491. Naunyn-Schmiedeberg's Archives of Pharmacology, 335, 12–20.Google Scholar
Kettler, R., Keller, H.H., Bonetti, E.P., et al (1985) Ro 16–6491: a new highly selective and reversible MAO-B inhibitor. Journal of Neurochemistry, 44 (Suppl.), S94.Google Scholar
Korn, A., Eichler, H.G., Fischbach, R., et al (1986) Moclobemide, a new reversible MAO inhibitor — interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology, 88, 153–157.Google Scholar
Korn, A., Da Prada, M., Raffesberg, W., et al (1988) Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. Journal of Neural Transmission, 26 (Suppl.), 57–71.Google Scholar
Kline, D.F. (1958) Clinical experience with iproniazid (Marsilid). Journal of Clinical and Experimental Psychopathology, 19 (1) (Suppl.), 72–78.Google Scholar
Lipper, S., Murphy, D.L., Slater, S., et al (1979) Comparative behavioural effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology, 62, 123–128.Google Scholar
McCarry, W.J., Callingham, B.A. & Mazel, P. (1987) Some in vitro effects of moclobemide on the anococcygeus muscle of the rat. Pharmocology and Toxicology, 60 (Suppl. 1), 34.Google Scholar
McGregor, D.D. (1965) The effect of sympathetic nerve stimulation on vasoconstrictor responses in perfused mesenteric blood vessels of the rat. Journal of Physiology, 177, 21–30.Google Scholar
Natoff, I.L. (1965) Toxic manifestations of foodstuffs during drug therapy with monoamine oxidase inhibitors. Medical Proceedings, 11, 101–104.Google Scholar
Ross, S.B. (1987) Pharmacological and toxicological exploitation of amine transporters. Trends in Pharmacological Sciences, 8, 227–231.Google Scholar
Strolin Benedetti, M., Kan, J.P. & Keane, P.E. (1979) A new specific reversible type A monoamine oxidase inhibitor: MD 780515. In Monoamine Oxidase: Structure, Functions and Altered Functions (eds Singer, T.P., Von Korff, R.W. & Murphy, D.L.). New York: Academic Press.Google Scholar
Strolin Benedetti, M., Boucher, T., Carlsson, A. & Fowler, C.J. (1983) Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochemical Pharmacology, 32, 47–52.Google Scholar
Tipton, K.F. (1986) Enzymology of monoamine oxidase. Cell Biochemistry and Function, 4, 79–87.Google Scholar
Youdim, M.B.H. & Finberg, J.P.L. (1983) Implications of MAO-A and MAO-B inhibition for antidepressant therapy. Modern Problems in Pharmacopsychiatry, 19, 177–188.Google Scholar
Waldmeier, P.C. (1985) On the reversibility of reversible MAO inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology, 329, 305–310.Google Scholar
Waldmeier, P.C., Felner, A.E. & Tipton, K.F. (1983) The monoamine oxidase inhibiting properties of CGP 11305 A. European Journal of Pharmacology, 94, 20–26.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.